SET Nuclear Oncogene (SET) Peptide
-
- Target See all SET/TAF-I (SET) products
- SET/TAF-I (SET) (SET Nuclear Oncogene (SET))
- Peptide Type
- Synthetic
- Origin
- Mammalian
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
- Sequence
- IDEVQNEIDR LNEQASEEIL KVEQKYNKLR QPFFQKRSEL IAKIPNFWVT
- Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of SET antibody,
Alternative Names: SET control peptide, SET antibody Blocking Peptide, Anti-SET Blocking Peptide, Set Nuclear Oncogene Blocking Peptide, 2PP2A Blocking Peptide, I2PP2A Blocking Peptide, IGAAD Blocking Peptide, PHAPII Blocking Peptide, TAF-IBETA Blocking Peptide
-
-
- Application Notes
- Optimal conditions should be determined by the investigator
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handling Advice
- Avoid repeated freeze/thaw cycles.
- Storage
- -20 °C
- Storage Comment
- Store at -20 °C long term.
-
- Target
- SET/TAF-I (SET) (SET Nuclear Oncogene (SET))
- Background
- SET is a multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone binding. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1.
- Molecular Weight
- 32 kDa
-